Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate: a 52-week phase III randomised study.
Clin Exp Rheumatol
; 40(5): 1025-1033, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-34251303
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Antirheumatic Agents
/
Biosimilar Pharmaceuticals
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Exp Rheumatol
Year:
2022
Type:
Article
Affiliation country:
Japan